(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
आज की मात्रा | 45.37M |
औसत मात्रा | 41.44M |
बाजार मूल्य | 157.04B |
EPS | $0 ( 2024-05-01 ) |
अगली कमाई की तारीख | ( $0 ) 2024-07-30 |
Last Dividend | $0.410 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -556.20 |
ATR14 | $0.0170 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Damico Jennifer B. | Buy | 55 | Phantom Stock Units SSP |
2024-04-30 | Bourla Albert | Buy | 20 | Phantom Stock Units SSP |
2024-04-25 | Quincey James | Buy | 8 116 | Phantom Stock Units |
2024-04-25 | Smith James C | Buy | 8 116 | Phantom Stock Units |
2024-04-25 | Nora Johnson Suzanne M | Buy | 8 116 | Phantom Stock Units |
INSIDER POWER |
---|
70.76 |
Last 100 transactions |
Buy: 4 322 762 | Sell: 745 543 |
मात्रा सहसंबंध
Pfizer Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
PCQ | 0.969 |
ZME | 0.962 |
CHGG | 0.951 |
RSF | 0.947 |
GDMA | 0.946 |
TPL | 0.941 |
CALX | 0.939 |
EVTL | 0.937 |
PCK | 0.936 |
K | 0.93 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
WWW | -0.954 |
HCI | -0.953 |
NGL-PB | -0.95 |
FSNB | -0.949 |
LOCC | -0.949 |
LHC | -0.948 |
VNT | -0.947 |
CRH | -0.945 |
FTAI | -0.942 |
JMP | -0.94 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Pfizer Inc सहसंबंध - मुद्रा/वस्त्र
Pfizer Inc वित्तीय
Annual | 2023 |
राजस्व: | $58.50B |
सकल लाभ: | $29.28B (50.06 %) |
EPS: | $0.380 |
FY | 2023 |
राजस्व: | $58.50B |
सकल लाभ: | $29.28B (50.06 %) |
EPS: | $0.380 |
FY | 2022 |
राजस्व: | $100.33B |
सकल लाभ: | $65.99B (65.77 %) |
EPS: | $5.59 |
FY | 2021 |
राजस्व: | $81.29B |
सकल लाभ: | $50.47B (62.08 %) |
EPS: | $3.92 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.400 (N/A) |
$0.400 (N/A) |
$0.410 (N/A) |
$0.410 (N/A) |
$0.410 (N/A) |
$0.410 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00316 | 1972-08-29 |
Last Dividend | $0.410 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-04 | |
Next Payout Date | N/A | |
# dividends | 206 | -- |
Total Paid Out | $26.05 | -- |
Avg. Dividend % Per Year | 2.24% | -- |
Score | 4.1 | -- |
Div. Sustainability Score | 1.990 | |
Div.Growth Potential Score | 2.67 | |
Div. Directional Score | 2.33 | -- |
Year | Amount | Yield |
---|---|---|
1972 | $0.00731 | 0.90% |
1973 | $0.0138 | 1.60% |
1974 | $0.0156 | 1.83% |
1975 | $0.0160 | 2.52% |
1976 | $0.0170 | 3.03% |
1977 | $0.0196 | 3.44% |
1978 | $0.0231 | 4.27% |
1979 | $0.0261 | 3.98% |
1980 | $0.0285 | 3.84% |
1981 | $0.0316 | 3.01% |
1982 | $0.0364 | 3.50% |
1983 | $0.0460 | 3.43% |
1984 | $0.0524 | 3.66% |
1985 | $0.0584 | 3.65% |
1986 | $0.0648 | 3.27% |
1987 | $0.0712 | 2.91% |
1988 | $0.0792 | 4.13% |
1989 | $0.0868 | 3.81% |
1990 | $0.0948 | 3.37% |
1991 | $0.104 | 3.29% |
1992 | $0.117 | 1.77% |
1993 | $0.133 | 2.32% |
1994 | $0.149 | 2.77% |
1995 | $0.164 | 2.74% |
1996 | $0.190 | 1.93% |
1997 | $0.215 | 1.66% |
1998 | $0.240 | 1.00% |
1999 | $0.291 | 0.75% |
2000 | $0.342 | 1.13% |
2001 | $0.416 | 0.95% |
2002 | $0.492 | 1.30% |
2003 | $0.568 | 1.90% |
2004 | $0.644 | 1.91% |
2005 | $0.720 | 2.87% |
2006 | $0.912 | 4.04% |
2007 | $1.100 | 4.41% |
2008 | $1.216 | 5.59% |
2009 | $0.760 | 4.39% |
2010 | $0.684 | 3.81% |
2011 | $0.760 | 4.53% |
2012 | $0.836 | 4.01% |
2013 | $0.912 | 3.71% |
2014 | $0.988 | 3.42% |
2015 | $1.064 | 3.58% |
2016 | $1.140 | 3.76% |
2017 | $1.216 | 3.88% |
2018 | $1.292 | 3.74% |
2019 | $1.368 | 3.33% |
2020 | $1.444 | 3.89% |
2021 | $1.560 | 4.24% |
2022 | $1.600 | 2.82% |
2023 | $1.640 | 3.20% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.00561 | 1.500 | -0.112 | -0.168 | [0 - 0.5] |
returnOnAssetsTTM | -0.00136 | 1.200 | -0.0455 | -0.0546 | [0 - 0.3] |
returnOnEquityTTM | -0.00320 | 1.500 | -1.147 | -1.720 | [0.1 - 1] |
payoutRatioTTM | -29.93 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.499 | 0.800 | -1.768 | -1.415 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.320 | -1.500 | 4.67 | -7.01 | [0 - 0.6] |
interestCoverageTTM | 0.531 | 1.000 | -0.914 | -0.914 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.538 | 2.00 | 9.49 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.847 | 2.00 | 9.58 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.814 | -1.500 | 6.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.507 | 1.000 | 4.89 | 4.89 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0258 | 1.000 | -1.483 | -1.483 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.120 | 1.000 | -0.444 | -0.444 | [0.2 - 2] |
assetTurnoverTTM | 0.243 | 0.800 | -1.712 | -1.369 | [0.5 - 2] |
Total Score | 1.990 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -509.13 | 1.000 | -10.00 | 0 | [1 - 100] |
returnOnEquityTTM | -0.00320 | 2.50 | -0.737 | -1.720 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.847 | 2.00 | 9.72 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 5.93 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.538 | 2.00 | 9.49 | 10.00 | [0 - 30] |
payoutRatioTTM | -29.93 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | 23.65 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.158 | 1.000 | 8.55 | 0 | [0.1 - 0.5] |
Total Score | 2.67 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं